CYP17 polymorphisms and prostate cancer outcomes.

  title={CYP17 polymorphisms and prostate cancer outcomes.},
  author={Jonathan L. Wright and Erika M. Kwon and Daniel W. Lin and Suzanne Kolb and Joseph S Koopmeiners and Ziding Feng and Elaine A Ostrander and Janet L. Stanford},
  journal={The Prostate},
  volume={70 10},
OBJECTIVE Cytochrome P450 17alpha-hydroxylases-C-(17,20)-lyase (CYP17) is a key enzyme involved with the androgen biosynthesis pathway and has recently been targeted for therapy in men with advanced prostate cancer (PCa). However, studies relating prostate cancer outcomes with CYP17 gene variants have conflicting results. In this study we analyzed Single Nucleotide Polymorphisms (SNPs) spanning the CYP17 gene for association with PCa survival. METHODS The cohort was comprised of Caucasian men… CONTINUE READING